Jerry Mitchell, MD
Medical Oncology · Powell, OHNPI 1750339651
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 41.1% of the total. Reporting peaked in 2019 at $19,797 and has fallen 99.7% since, to $63 in 2025.
Across 136 payments — averaging $204.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$11K
- Sun Pharmaceutical Industries Inc.$5K
- Rigel Pharmaceuticals, Inc.$4K
- Seagen Inc.$2K
- Sanofi$2K
- Novartis$1K
- plus $2K from 28 others
What the payments were for
- Consulting fees$14,75453%
- Speaking & faculty fees$7,25226%
- Travel & lodging$1,8046%
- Food & beverage$2,3388%
- Education$2291%
- Gifts$1,4275%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $11,439 |
| Sun Pharmaceutical Industries Inc. | 9 | $5,239 |
| Rigel Pharmaceuticals, Inc. | 4 | $4,145 |
| Seagen Inc. | 10 | $1,774 |
| Sanofi | 7 | $1,539 |
| Novartis | 20 | $1,440 |
| Bristol Myers Squibb | 5 | $961 |
| Eisai Inc. | 12 | $177 |
| Exelixis Inc. | 6 | $169 |
| Amgen | 6 | $136 |
| Taiho Oncology, Inc. | 7 | $94 |
| Foundation Medicine, Inc. | 3 | $76 |
| Beigene USA, Inc. | 4 | $76 |
| AbbVie | 2 | $63 |
| GSK | 2 | $60 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Merck | 3 | $47 |
| AstraZeneca(2 entities) | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Dendreon Pharmaceuticals LLC | 2 | $25 |
| EMD Serono, Inc. | 2 | $24 |
| Dova Pharmaceuticals | 2 | $23 |
| Johnson & Johnson | 2 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Innate Pharma, Inc | 1 | $19 |
| Acceleron Pharma, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Secura Bio, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,804 in reported general payments places this provider in the 80th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 40 | $1,017 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Powell
- David CarboneColumbus$438K
- Elyse LowerCincinnati$312K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Mark MarinellaKettering$84K
- Timothy BurnsColumbus$64K
- William TseCleveland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.